Walter Stummer
Department of Neurosurgery, University Hospital Münster, Münster, Germany, 48149 · University Hospital Muenster · University Hospital Muenster, Klinik und Poliklinik für Neurochirurgie
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Walter Stummer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:24 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06665724 · Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)Universität Münster · completed · Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Glioblastoma (GBM) · principal investigator
- Ph1/Ph2NCT05590689 · Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain TumorUniversität Münster · recruiting · Glioblastoma · principal investigator
- Ph1NCT05533242 · Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard TreatmentUniversity Hospital Muenster · terminated · Glioblastom WHO Grade 4 · principal investigator
- Ph2NCT04738162 · Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain TumorsUniversität Münster · completed · Brain Tumor, Pediatric · principal investigator
- Ph2NCT04469699 · Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent GlioblastomaUniversity Hospital Muenster · terminated · Glioblastoma Multiforme, Adult · principal investigator
- Ph3NCT04305470 · Gleolan for Visualization of Newly Diagnosed or Recurrent MeningiomaNX Development Corp · completed · Meningioma · principal investigator
- Ph2NCT03897491 · PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastomaphotonamic GmbH & Co. KG · terminated · Glioblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 09:24 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.Neurosurgery · 2008808 citationsRCR 24.5
- 452 citationsRCR 19.6
- Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.Neuro Oncol · 2008260 citationsRCR 7.4
- Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.J Clin Oncol · 2016151 citationsRCR 5.1
- ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment.J Environ Pathol Toxicol Oncol · 2007125 citationsRCR 3.8
- Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.J Neurooncol · 201161 citationsRCR 2.1
- 41 citationsRCR 1.8
- Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.Neuro Oncol · 201816 citationsRCR 0.8